Literature DB >> 17319558

A comparison of oral and implant naltrexone outcomes at 12 months.

Ross Colquhoun1, Donald Y K Tan, Samantha Hull.   

Abstract

Naltrexone's current use has been limited by compliance. Subcutaneous implants would seem to offer a solution to this problem and improve long-term outcomes. The aim of the present study was to compare groups of patients who had received oral naltrexone or a naltrexone implant after detoxification and to follow their progress. Forty-one patients received an implant, and 42 patients received oral naltrexone. They were surveyed at one, three, six, and 12 months after detoxification. Their designated support person was also contacted to confirm the self-reports of the participants. Patients were compared on gender, age, and length of time since detoxification. Implant patients showed much higher abstinence rates, while those in both groups who were abstinent showed greater compliance to naltrexone (time spent in treatment) and attended more counseling sessions. Although the participants were not randomly allocated to each treatment condition, the preliminary evidence indicates that implants can improve compliance rates and outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 17319558     DOI: 10.5055/jom.2005.0054

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  10 in total

1.  Advances in opioid antagonist treatment for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Li-Tzy Wu
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

2.  Improved parameters of metabolic glycaemic and immune function and arterial stiffness with naltrexone implant therapy.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2009-04-14

3.  Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment.

Authors:  Adam C Brooks; Sandra D Comer; Maria A Sullivan; Adam Bisaga; Kenneth M Carpenter; Wilfrid M Raby; Elmer Yu; Charles P O'Brien; Edward V Nunes
Journal:  J Clin Psychiatry       Date:  2010-07-13       Impact factor: 4.384

Review 4.  A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here.

Authors:  Walter Ling
Journal:  J Neuroimmune Pharmacol       Date:  2016-03-23       Impact factor: 4.147

5.  A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.

Authors:  Maria A Sullivan; Adam Bisaga; Martina Pavlicova; Kenneth M Carpenter; C Jean Choi; Kaitlyn Mishlen; Frances R Levin; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2018-10-19       Impact factor: 18.112

6.  Pharmacological enhancement of naltrexone treatment for opioid dependence: a review.

Authors:  Paolo Mannelli; Kathleen S Peindl; Li-Tzy Wu
Journal:  Subst Abuse Rehabil       Date:  2011-06

7.  Long-acting Preparations in Substance Abuse Management: A Review and Update.

Authors:  Aditya Hegde; Shubh Mohan Singh; Siddharth Sarkar
Journal:  Indian J Psychol Med       Date:  2013-01

Review 8.  Naltrexone Implant for Opioid Use Disorder.

Authors:  Amber N Edinoff; Catherine A Nix; Claudia V Orellana; Samantha M StPierre; Erin A Crane; Blaine T Bulloch; Elyse M Cornett; Rachel L Kozinn; Adam M Kaye; Kevin S Murnane; Alan D Kaye
Journal:  Neurol Int       Date:  2021-12-30

9.  Open label trial of naltrexone implants: measuring blood serum levels of naltrexone.

Authors:  Ross M Colquhoun
Journal:  Subst Abuse       Date:  2013-05-15

Review 10.  Selective review and commentary on emerging pharmacotherapies for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Min Zhao; Suzanne Nielsen; Matthew Torrington; Karen Miotto
Journal:  Subst Abuse Rehabil       Date:  2011-10-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.